Delivery Order SPE2DB22D3102-SPE2DB25FL2HB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $13,611.53. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, under a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,573.03 delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child award under a larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $1,613.70 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg. This contract employs a firm fixed price delivery order structure with no set-aside designation, indicating competitive award. The pharmaceutical product will be supplied to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,738.42 on August 5, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules (1,000 count). This award is non-competitive and carries a firm fixed price structure with completion targeted for August 6, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under a larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules under a firm fixed price contract valued at $2,008.55. The delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 6, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $10,368.01. This is a firm fixed-price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was awarded competitively with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,609.16 to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, with delivery expected by July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value pharmaceutical procurement supporting military healthcare supply needs. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a common medication used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $11,771.03, is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication used to treat benign prostatic hyperplasia. The contract is firm fixed price with a ceiling value of $10,078.41 and an ultimate completion date of August 15, 2025. This is a non-set-aside competitive award, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for 1,000 units of the medication Tamsulosin Hydrochloride 0.4 mg capsules, with a firm fixed price of $1,230.30 and a period of performance through July 2, 2025. AmerisourceBergen holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL2HBDelivery Order
The Defense Logistics Agency awarded a $1,140.59 delivery order to AmerisourceBergen Drug Corp for 500 capsules of Tamsulosin HCL 0.4 mg, with a completion date of July 30, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving military and veteran healthcare systems. The company maintains an extensive portfolio of federal contract awards with DLA covering a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains. This particular delivery order for Tamsulosin HCL, a medication commonly used to treat urinary symptoms associated with benign prostatic hyperplasia, is consistent with the contractor's role as a primary supplier of both brand-name and generic medications to support federal healthcare programs, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/29/25 |